ES2164704T3 - Derivados en posicion 36 de rifamicinas y su uso como agentes antimicrobianos. - Google Patents

Derivados en posicion 36 de rifamicinas y su uso como agentes antimicrobianos.

Info

Publication number
ES2164704T3
ES2164704T3 ES94916937T ES94916937T ES2164704T3 ES 2164704 T3 ES2164704 T3 ES 2164704T3 ES 94916937 T ES94916937 T ES 94916937T ES 94916937 T ES94916937 T ES 94916937T ES 2164704 T3 ES2164704 T3 ES 2164704T3
Authority
ES
Spain
Prior art keywords
pct
image
alkylamino
sec
antimicrobial agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94916937T
Other languages
English (en)
Inventor
Emilio Occelli
Sergio Lociuro
Romeo Ciabatti
Maurizio Denaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Bulk SpA
Original Assignee
Aventis Bulk SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Bulk SpA filed Critical Aventis Bulk SpA
Application granted granted Critical
Publication of ES2164704T3 publication Critical patent/ES2164704T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

DERIVADOS ANTIBIOTICOS DE RIFAMICINAS DE LAS FORMULAS (I) Y (IA) QUE TIENEN EN LA POSICION 36 UN SUSTITUYENTE SELECCIONADO DEL ALQUILO (C{SUB,1}-C{SUB,8}), HALO, HIDROXI, ACILOXI (C{SUB,1}-C{SUB,4}), ALCOXI (C{SUB,1}-C{SUB,4}), ALQUILAMINO (C{SUB,1}-C{SUB,4}), DIALQUILAMINO (C{SUB,1}-C{SUB,4}) Y CARBONILOXI DE 4-OXO-3-PIRIDINILO SUSTITUIDO DE LA FORMULA (1) SE OBTIENEN HACIENDO REACCIONAR RIFAMICINA CON UN ACIDO MALONICO SUSTITUIDO DE FORMA ADECUADA. LOS COMPUESTOS DE LA INVENCION SON AGENTES ANTIMICROBIANOS PRINCIPALMENTE ACTIVOS CONTRA LAS BACTERIAS GRAM POSITIVAS Y BACTERIAS GRAM NEGATIVAS MALIGNAS Y PRESENTAN TAMBIEN UNA ACTIVIDAD ANTIMICROBIANA CONSIDERABLE CONTRA LAS ESPECIES MICROBIANAS RESISTENTES A LA RIFAMPICINA.
ES94916937T 1993-05-24 1994-05-05 Derivados en posicion 36 de rifamicinas y su uso como agentes antimicrobianos. Expired - Lifetime ES2164704T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93108337 1993-05-24
EP93110315 1993-06-29

Publications (1)

Publication Number Publication Date
ES2164704T3 true ES2164704T3 (es) 2002-03-01

Family

ID=26133222

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94916937T Expired - Lifetime ES2164704T3 (es) 1993-05-24 1994-05-05 Derivados en posicion 36 de rifamicinas y su uso como agentes antimicrobianos.

Country Status (12)

Country Link
US (1) US5786350A (es)
JP (1) JP3566962B2 (es)
KR (1) KR100325562B1 (es)
AT (1) ATE206427T1 (es)
AU (1) AU687817B2 (es)
CA (1) CA2160243C (es)
DE (1) DE69428535T2 (es)
DK (1) DK0700399T3 (es)
ES (1) ES2164704T3 (es)
IL (1) IL109691A (es)
PT (1) PT700399E (es)
WO (1) WO1994028002A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009815A2 (en) 2001-07-25 2003-02-06 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
WO2003045319A2 (en) * 2001-11-21 2003-06-05 Activbiotics, Inc. Targeted therapeutics and uses thereof
US7820652B2 (en) * 2003-09-24 2010-10-26 Activbiotics Pharma, Llc Regimen for the administration of rifamycin-class antibiotics
EP1723150A1 (en) * 2004-01-13 2006-11-22 Cumbre Pharmaceuticals Inc. Rifamycin imino derivatives effective against drug-resistant microbes
US7247634B2 (en) * 2004-01-13 2007-07-24 Cumbre Pharmaceuticals Inc. Rifamycin derivatives effective against drug-resistant microbes
US7256187B2 (en) 2004-03-10 2007-08-14 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime derivatives effective against drug-resistant microbes
US7265107B2 (en) 2004-03-10 2007-09-04 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes
US7250413B2 (en) * 2004-04-26 2007-07-31 Cumbre Pharmaceuticals Inc. C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes
DE602005013671D1 (de) * 2004-07-22 2009-05-14 Cumbre Pharmaceuticals Inc (r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen
EP3827747A1 (en) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
EP3395372B1 (en) 2009-02-20 2022-04-06 EnhanX Biopharm Inc. Glutathione-based drug delivery system
IL255113B (en) 2009-05-06 2022-09-01 Laboratory Skin Care Inc Preparations for administration through the skin that include complexes of an active substance with calcium phosphate and methods of using them
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CA2886264A1 (en) * 2012-09-12 2014-03-20 Salix Pharmaceuticals, Inc. Methods of administering rifaximin without producing antibiotic resistance
AR114309A1 (es) * 2018-01-24 2020-08-19 Univ Rockefeller Compuestos antibacterianos, composiciones de los mismos, y métodos que utilizan los mismos
US11339184B2 (en) 2019-07-23 2022-05-24 The Rockefeller University Antibacterial compounds, compositions thereof, and methods using same
WO2024068926A1 (en) 2022-09-30 2024-04-04 BioVersys AG Rifabutin analogs for the treatment of disease

Also Published As

Publication number Publication date
US5786350A (en) 1998-07-28
ATE206427T1 (de) 2001-10-15
CA2160243C (en) 2007-08-28
DK0700399T3 (da) 2001-11-26
PT700399E (pt) 2002-02-28
WO1994028002A1 (en) 1994-12-08
KR960702466A (ko) 1996-04-27
CA2160243A1 (en) 1994-12-08
JPH08511249A (ja) 1996-11-26
DE69428535T2 (de) 2002-08-01
DE69428535D1 (de) 2001-11-08
IL109691A0 (en) 1994-08-26
KR100325562B1 (ko) 2002-07-22
JP3566962B2 (ja) 2004-09-15
AU6843094A (en) 1994-12-20
IL109691A (en) 1998-10-30
AU687817B2 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
ES2164704T3 (es) Derivados en posicion 36 de rifamicinas y su uso como agentes antimicrobianos.
SI0868424T1 (en) 4-pyrimidinyl- or 4-pyrazinyl-piperazinyl-phenyl-oxazolidinone derivatives, their preparation and their use as anti-bacterial agents
WO2005014585A8 (en) Halogenated quinazolinyl nitrofurans as antibacterial agents
AU686222B2 (en) Cyclodepsipeptide compound
GB0007405D0 (en) Compounds
PL377226A1 (pl) N-Alkilo-4-metylenoamino-3-hydroksy-2- pirydony jako środki przeciw drobnoustrojom
KR970705392A (ko) 신규한 항생제 조성물 및 그람-양성 세균 및 마이코플라스마 감염의 치료 방법(novel antibiotic compounds and methods to treat grampositive bacterial and mycoplasmal infections)
BR0016605A (pt) Oxazolidinonas possuindo uma funcionalidade sulfoximina e seus usos como agente antimicrobiano
HRP20050517B1 (hr) N-sulfonil-4-metilenamino-3-hidroksi-2-piridoni kao antimikrobni lijekovi
PL344049A1 (en) Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives
TR200001330T2 (tr) Oksazolidinon türevleri ve farmasötik terkipler
NZ503897A (en) 3,6-hemiketals from the class of 9a-azalides
BR0015177A (pt) ésteres de ácido benzóico de oxazolidinonas possuindo um substituinte hidroxiacetilpiperazina
AU4540096A (en) Basic oxazoline-amide derivatives of ge 2270 and ge 2270-like antibiotics
AU2001278428A1 (en) Macrolides
AU6076500A (en) Hypoestoxides, derivatives and agonists thereof for use as antiparasitic agents
BR0312550A (pt) Derivados de nocatiacina o-derivatizados
ES2120500T3 (es) 4'-metoxiacetofenonas halogenadas como microbicidas y conservantes.
WO2002080918A1 (fr) Agent therapeutique ou prophylactique en cas de miction frequente ou d'incontinence urinaire
GB9115272D0 (en) Benzimidazole anthelmintics
MXPA05009243A (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados.
BR0108758A (pt) Ecta antiinfectivo
TR200102019T2 (tr) 3-izoksazolidinonların ve hidroksilamik asitlerin enfeksiyonların tedavisinde kullanılmaları.
ES2114477B1 (es) Nuevas cafalosporinas.
ES2156533B1 (es) Nuevo derivado de adenilfosfato como inhibidor de aminoacil arn-t-sintetasas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 700399

Country of ref document: ES